$NMTC
NEUROONE MEDICAL TECHNOLOGIES Corp Stock $nmtc

$nmtc Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000121390024042948 Filed on May 14, 2024

Income Statement

Concept	2024 Q2	2024 Q1	2023 Q1
Revenue	$825.8K	$1.377M	$466.2K
YoY Change	31.1%	195.45%	1174.4%
Cost Of Revenue	$543.9K	$986.9K	$434.7K
YoY Change	40.82%	127.04%	497.0%
Gross Profit	$281.9K	$390.4K	$31.50K
YoY Change	15.68%	1139.31%	-186.95%
Gross Profit Margin	34.13%	28.35%	6.76%
Selling, General & Admin	$1.881M	$2.003M	$1.821M
YoY Change	1.0%	9.99%	0.16%
% of Gross Profit	667.36%	513.03%	5780.74%
Research & Development	$1.195M	$1.274M	$1.706M
YoY Change	-36.84%	-25.36%	41.56%
% of Gross Profit	423.84%	326.21%	5416.35%
Depreciation & Amortization	$57.53K	$55.32K	$38.33K
YoY Change	11.97%	44.32%	34.35%
% of Gross Profit	20.41%	14.17%	121.67%
Operating Expenses	$3.076M	$3.277M	$3.527M
YoY Change	-18.06%	-7.11%	16.66%
Operating Profit	-$2.794M	-$2.886M	-$3.496M
YoY Change	-20.41%	-17.44%	14.25%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net	$26.38K	$31.01K	-$26.91K
YoY Change	-36.38%	-215.23%	-1646.55%
Pretax Income	-$2.768M	-$2.855M	-$3.523M
YoY Change	-20.22%	-18.95%	15.2%
Income Tax
% Of Pretax Income
Net Earnings	-$2.768M	-$2.855M	-$3.523M
YoY Change	-20.22%	-18.95%	15.2%
Net Earnings / Revenue	-335.14%	-207.3%	-755.69%
Basic Earnings Per Share	-$0.10	-$0.11	-$0.21
Diluted Earnings Per Share	-$0.10	-$0.11	-$0.21
COMMON SHARES
Basic Shares Outstanding	27.52M shares	25.93M shares	16.36M shares
Diluted Shares Outstanding	27.35M shares	25.91M shares	16.41M shares

Balance Sheet

Concept	2024 Q2	2024 Q1	2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.620M	$2.435M	$4.598M
YoY Change	-47.46%	-47.04%	-64.27%
Cash & Equivalents	$1.620M	$2.435M	$3.602M
Short-Term Investments			$995.4K
Other Short-Term Assets	$261.5K	$407.8K	$370.7K
YoY Change	-6.21%	10.0%	17.65%
Inventory	$1.793M	$1.312M	$1.174M
Prepaid Expenses			$370.7K
Receivables	$410.6K	$555.6K	$214.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$4.085M	$4.710M	$6.357M
YoY Change	-16.26%	-25.91%	-52.71%
LONG-TERM ASSETS
Property, Plant & Equipment	$472.5K	$496.0K	$522.8K
YoY Change	-19.49%	-5.13%	-0.04%
Goodwill
YoY Change
Intangibles	$72.84K	$78.42K	$100.7K
YoY Change	-23.45%	-22.15%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$827.2K	$685.2K	$848.5K
YoY Change	-5.94%	-19.26%	31.35%
TOTAL ASSETS
Total Short-Term Assets	$4.085M	$4.710M	$6.357M
Total Long-Term Assets	$827.2K	$685.2K	$848.5K
Total Assets	$4.913M	$5.395M	$7.205M
YoY Change	-14.68%	-25.12%	-48.86%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$759.3K	$780.8K	$953.4K
YoY Change	-20.81%	-18.1%	113.77%
Accrued Expenses	$931.7K	$759.6K	$596.9K
YoY Change	18.07%	27.25%	64.92%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$121.9K	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.691M	$1.540M	$1.550M
YoY Change	-3.26%	-0.64%	91.35%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$209.9K	$0.00	$121.9K
YoY Change	136.07%	-100.0%	-21.88%
Total Long-Term Liabilities	$209.9K	$0.00	$121.9K
YoY Change	136.07%	-100.0%	-21.88%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.691M	$1.540M	$1.550M
Total Long-Term Liabilities	$209.9K	$0.00	$121.9K
Total Liabilities	$1.901M	$1.540M	$1.672M
YoY Change	3.49%	-7.88%	73.07%
SHAREHOLDERS EQUITY
Retained Earnings	-$71.70M	-$68.90M	-$56.10M
YoY Change	20.4%	22.82%
Common Stock	$27.85K	$26.32K	$16.89K
YoY Change	55.9%	55.86%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$3.012M	$3.854M	$5.533M
YoY Change
Total Liabilities & Shareholders Equity	$4.913M	$5.395M	$7.205M
YoY Change	-14.68%	-25.12%	-48.86%

Cashflow Statement

Concept	2024 Q2	2024 Q1	2023 Q1
OPERATING ACTIVITIES
Net Income	-$2.768M	-$2.855M	-$3.523M
YoY Change	-20.22%	-18.95%	15.2%
Depreciation, Depletion And Amortization	$57.53K	$55.32K	$38.33K
YoY Change	11.97%	44.32%	34.35%
Cash From Operating Activities	-$2.360M	-$2.175M	-$3.552M
YoY Change	-19.72%	-38.75%	10.24%
INVESTING ACTIVITIES
Capital Expenditures	$14.80K	$31.36K	$175.7K
YoY Change	-89.37%	-82.15%	-288.28%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	$2.000M
YoY Change	-100.0%	-100.0%
Cash From Investing Activities	-$14.80K	-$31.36K	$1.824M
YoY Change	-101.72%	-101.72%	-2054.9%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.561M	1.960M	662.0K
YoY Change	-0.02%	196.12%	-206962.5%
NET CHANGE
Cash From Operating Activities	-2.360M	-2.175M	-3.552M
Cash From Investing Activities	-14.80K	-31.36K	1.824M
Cash From Financing Activities	1.561M	1.960M	662.0K
Net Change In Cash	-814.7K	-246.3K	-1.065M
YoY Change	57.06%	-76.88%	-67.87%
FREE CASH FLOW
Cash From Operating Activities	-$2.360M	-$2.175M	-$3.552M
Capital Expenditures	$14.80K	$31.36K	$175.7K
Free Cash Flow	-$2.375M	-$2.207M	-$3.727M
YoY Change	-22.87%	-40.8%	19.15%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.32
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	25910478	shares
	nmtc	Revenue From Collaboration RevenueFromCollaboration		usd
CY2022Q4	nmtc	Stock Issued During Period Value Restricted Stock Unit Gross StockIssuedDuringPeriodValueRestrictedStockUnitGross		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2024-03-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-40439
	dei	Entity Registrant Name EntityRegistrantName	NeuroOne Medical Technologies Corporation
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	27-0863354
	dei	Entity Address Address Line1 EntityAddressAddressLine1	7599 Anagram Drive
	dei	Entity Address City Or Town EntityAddressCityOrTown	Eden Prairie
	dei	Entity Address State Or Province EntityAddressStateOrProvince	MN
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	55344
	dei	City Area Code CityAreaCode	952
	dei	Local Phone Number LocalPhoneNumber	426-1383
	dei	Security12b Title Security12bTitle	Common stock, $0.001 par value
	dei	Trading Symbol TradingSymbol	NMTC
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	27515921	shares
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2434655	usd
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5322493	usd
CY2024Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	555639	usd
CY2024Q1	us-gaap	Inventory Net InventoryNet	1311673	usd
CY2023Q3	us-gaap	Inventory Net InventoryNet	1726686	usd
CY2024Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	407777	usd
CY2023Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	263746	usd
CY2024Q1	us-gaap	Assets Current AssetsCurrent	4709744	usd
CY2023Q3	us-gaap	Assets Current AssetsCurrent	7312925	usd
CY2024Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	78419	usd
CY2023Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	89577	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	110724	usd
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	169059	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	496015	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	525753	usd
CY2024Q1	us-gaap	Assets Assets	5394902	usd
CY2023Q3	us-gaap	Assets Assets	8097314	usd
CY2024Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	780839	usd
CY2023Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	685104	usd
CY2024Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	759620	usd
CY2023Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1107522	usd
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	1540459	usd
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	1792626	usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	55284	usd
CY2024Q1	us-gaap	Liabilities Liabilities	1540459	usd
CY2023Q3	us-gaap	Liabilities Liabilities	1847910	usd
CY2024Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2024Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	26321750	shares
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	26321750	shares
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	23928945	shares
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	23928945	shares
CY2024Q1	us-gaap	Common Stock Value CommonStockValue	26322	usd
CY2023Q3	us-gaap	Common Stock Value CommonStockValue	23929	usd
CY2024Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	72714414	usd
CY2023Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	68911778	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-68886293	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-62686303	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	3854443	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	6249404	usd
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	5394902	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	8097314	usd
CY2024Q1	us-gaap	Revenues Revenues	1377294	usd
CY2023Q1	us-gaap	Revenues Revenues	466176	usd
	us-gaap	Revenues Revenues	2354943	usd
	us-gaap	Revenues Revenues	580755	usd
CY2024Q1	us-gaap	Cost Of Revenue CostOfRevenue	986875	usd
CY2023Q1	us-gaap	Cost Of Revenue CostOfRevenue	434673	usd
	us-gaap	Cost Of Revenue CostOfRevenue	1698210	usd
	us-gaap	Cost Of Revenue CostOfRevenue	561559	usd
CY2024Q1	us-gaap	Gross Profit GrossProfit	390419	usd
CY2023Q1	us-gaap	Gross Profit GrossProfit	31503	usd
	us-gaap	Gross Profit GrossProfit	656733	usd
	us-gaap	Gross Profit GrossProfit	19196	usd
	nmtc	Revenue From Collaboration RevenueFromCollaboration	1455188	usd
CY2024Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2002949	usd
CY2023Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1821108	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	4176421	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	3484845	usd
CY2024Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1273568	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1706314	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2756885	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3269810	usd
CY2024Q1	us-gaap	Operating Expenses OperatingExpenses	3276517	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	3527422	usd
	us-gaap	Operating Expenses OperatingExpenses	6933306	usd
	us-gaap	Operating Expenses OperatingExpenses	6754655	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-2886098	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-3495919	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-6276573	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-5280271	usd
CY2024Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	31008	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-26909	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	76583	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	24674	usd
CY2024Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2855090	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3522828	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-6199990	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-5255597	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-2855090	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-3522828	usd
	us-gaap	Net Income Loss NetIncomeLoss	-6199990	usd
	us-gaap	Net Income Loss NetIncomeLoss	-5255597	usd
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.11
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.21
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.25
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.32
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	25910478	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	16414795	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	24947813	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	16321891	shares
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	9604364	usd
CY2022Q4	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	300181	usd
CY2022Q4	us-gaap	Net Income Loss NetIncomeLoss	-1732769	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	8171776	usd
CY2023Q1	nmtc	Stock Issued During Period Value Issuance Of Common Stock In Connection With Atthemarket Offering Program StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithAtthemarketOfferingProgram	928257	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	-183359	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	237628	usd
CY2023Q1	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	98650	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-3522828	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	5532824	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	6249404	usd
CY2023Q4	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1256271	usd
CY2023Q4	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	37698	usd
CY2023Q4	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	308638	usd
CY2023Q4	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	13559	usd
CY2023Q4	us-gaap	Net Income Loss NetIncomeLoss	-3344900	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	4418156	usd
CY2024Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	2094196	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	148382	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	356858	usd
CY2024Q1	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	11295	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-2855090	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	3854443	usd
	us-gaap	Net Income Loss NetIncomeLoss	-6199990	usd
	us-gaap	Net Income Loss NetIncomeLoss	-5255597	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	119557	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	79799	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	665496	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	537809	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	41003	usd
	nmtc	Noncash Lease Expense NoncashLeaseExpense	-58335	usd
	nmtc	Noncash Lease Expense NoncashLeaseExpense	-53886	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	555639	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	180715	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-415013	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	469769	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	144031	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	74054	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	76899	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-24862	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-420194	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-1669283	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5984554	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-7043789	usd
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	1473419	usd
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	3500000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	68491	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	187206	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-68491	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	1839375	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	3350467	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	928257	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	160406	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	183359	usd
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	24854	usd
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	98650	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3165207	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	646248	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-2887838	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-4558166	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5322493	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	8160329	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2434655	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3602163	usd
	nmtc	Unpaid Deferred Issuance Costsoffset In Prepaids And Other Assets UnpaidDeferredIssuanceCostsoffsetInPrepaidsAndOtherAssets	25674	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	97536	usd
	nmtc	Purchased Property And Equipment In Accounts Payable PurchasedPropertyAndEquipmentInAccountsPayable	14800	usd
	nmtc	Purchased Property And Equipment In Accounts Payable PurchasedPropertyAndEquipmentInAccountsPayable	50646	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-68900000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Management’s Use of Estimates</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p>
CY2024Q1	us-gaap	Advertising Expense AdvertisingExpense	15781	usd
	us-gaap	Advertising Expense AdvertisingExpense	65053	usd
CY2023Q1	us-gaap	Advertising Expense AdvertisingExpense	53613	usd
	us-gaap	Advertising Expense AdvertisingExpense	106639	usd
	nmtc	Number Of Days To Remedy Default NumberOfDaysToRemedyDefault	P90D
CY2024Q1	us-gaap	Royalty Expense RoyaltyExpense	37500	usd
CY2023Q1	us-gaap	Royalty Expense RoyaltyExpense	37500	usd
	us-gaap	Royalty Expense RoyaltyExpense	75000	usd
	us-gaap	Royalty Expense RoyaltyExpense	75000	usd
	us-gaap	Operating Lease Lease Income Lease Payments OperatingLeaseLeaseIncomeLeasePayments	86105	usd
CY2023Q1	us-gaap	Operating Lease Lease Income Lease Payments OperatingLeaseLeaseIncomeLeasePayments	43053	usd
	us-gaap	Operating Lease Lease Income Lease Payments OperatingLeaseLeaseIncomeLeasePayments	85527	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	68673	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	66493	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	97536	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	110724	usd
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	169059	usd
CY2024Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	121896	usd
CY2023Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	184400	usd
CY2024Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P0Y10M24D
CY2023Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y4M24D
CY2024Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.077	pure
CY2023Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.078	pure
CY2024Q1	nmtc	Lessee Operating Lease Liability To Be Paid Remainder Of Calendar Year LesseeOperatingLeaseLiabilityToBePaidRemainderOfCalendarYear	105365	usd
CY2024Q1	nmtc	Lessee Operating Lease Liability Payments Due Fiscal Year LesseeOperatingLeaseLiabilityPaymentsDueFiscalYear	21227	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	126592	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	4696	usd
CY2024Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	121896	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	121896	usd
CY2024Q1	us-gaap	Inventory Gross InventoryGross	850271	usd
CY2023Q3	us-gaap	Inventory Gross InventoryGross	1202778	usd
CY2024Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	461402	usd
CY2023Q3	us-gaap	Inventory Work In Process InventoryWorkInProcess	343597	usd
CY2023Q3	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	180311	usd
CY2024Q1	us-gaap	Inventory Net InventoryNet	1311673	usd
CY2023Q3	us-gaap	Inventory Net InventoryNet	1726686	usd
CY2023Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	89577	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	11158	usd
CY2024Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	78419	usd
CY2024Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	5579	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	11158	usd
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	5579	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	11158	usd
CY2024Q1	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	939398	usd
CY2023Q3	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	860737	usd
CY2024Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	939398	usd
CY2023Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	860737	usd
CY2024Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	443383	usd
CY2023Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	334984	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	496015	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	525753	usd
CY2024Q1	us-gaap	Depreciation Depreciation	55321	usd
	us-gaap	Depreciation Depreciation	108399	usd
CY2023Q1	us-gaap	Depreciation Depreciation	38331	usd
	us-gaap	Depreciation Depreciation	68641	usd
CY2024Q1	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	579071	usd
CY2023Q3	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	874382	usd
CY2024Q1	us-gaap	Short Term Borrowings ShortTermBorrowings	121896	usd
CY2023Q3	us-gaap	Short Term Borrowings ShortTermBorrowings	129116	usd
CY2024Q1	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	41646	usd
CY2023Q3	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	104024	usd
CY2024Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	17007	usd
CY2024Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	759620	usd
CY2023Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1107522	usd
CY2022	us-gaap	Payments For Fees PaymentsForFees	2000000	usd
CY2022Q3	us-gaap	Payment For Management Fee PaymentForManagementFee	3500000	usd
CY2022	us-gaap	Warrant Exercise Price Increase WarrantExercisePriceIncrease	3
	nmtc	Transaction Price Associated With The Development Agreement TransactionPriceAssociatedWithTheDevelopmentAgreement	5400000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	100000	usd
CY2022Q3	us-gaap	Deferred Revenue DeferredRevenue	1455188	usd
	us-gaap	Recognition Of Deferred Revenue RecognitionOfDeferredRevenue	-1455188	usd
CY2024Q1	us-gaap	Revenues Revenues	1377294	usd
	us-gaap	Revenues Revenues	2354943	usd
CY2023Q1	us-gaap	Revenues Revenues	466176	usd
	us-gaap	Revenues Revenues	580755	usd
CY2024Q1	us-gaap	Other Selling General And Administrative Expense OtherSellingGeneralAndAdministrativeExpense	280516	usd
CY2023Q1	us-gaap	Other Selling General And Administrative Expense OtherSellingGeneralAndAdministrativeExpense	199467	usd
	us-gaap	Other Selling General And Administrative Expense OtherSellingGeneralAndAdministrativeExpense	523714	usd
	us-gaap	Other Selling General And Administrative Expense OtherSellingGeneralAndAdministrativeExpense	454932	usd
CY2024Q1	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	76342	usd
CY2023Q1	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	38161	usd
	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	141782	usd
	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	82877	usd
CY2024Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	356858	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	237628	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	665496	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	537809	usd
	nmtc	Shares Outstanding Percentage SharesOutstandingPercentage	0.13	pure
CY2024Q1	nmtc	Option Plan Shares OptionPlanShares	1051556	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	65000	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	56781	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1225669	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	130512	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.91
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.88
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.08
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.75
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2879096	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1708427	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	1.117	pure
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	0.581	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	1.119	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	0.555	pure
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y3M18D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y1M6D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y2M12D
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.043	pure
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.037	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.046	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.039	pure
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	48295	shares
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	84778	shares
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares	0	shares
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares	0	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	104911	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	212224	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares	55000	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares	0	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	183130	shares
CY2024Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	3100000	usd
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y8M12D
	us-gaap	Concentration Risk Customer ConcentrationRiskCustomer	One
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2024Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2023Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2022Q4	nmtc	Maximum Aggregate Common Stock Offering Price MaximumAggregateCommonStockOfferingPrice	14500000	usd
CY2022Q4	nmtc	Fixed Commission Rate FixedCommissionRate	0.03	pure
CY2023Q3	nmtc	Maximum Aggregate Common Stock Offering Price MaximumAggregateCommonStockOfferingPrice	2600000	usd
CY2023Q4	nmtc	Maximum Aggregate Common Stock Offering Price MaximumAggregateCommonStockOfferingPrice	4800000	usd
CY2024Q1	nmtc	Maximum Aggregate Common Stock Offering Price MaximumAggregateCommonStockOfferingPrice	9300000	usd
	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	1461353	shares
CY2024Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	2329596	shares
CY2024Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	2094196	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	3350467	usd
CY2023Q4	us-gaap	Shares Issued SharesIssued	5903123	shares
CY2023Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	516484	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	928257	usd
CY2023Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	183359	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	183359	usd
CY2024Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	usd
	nmtc	Warrant Expired WarrantExpired	279727	shares
CY2024Q1	nmtc	Warrant Expired WarrantExpired	1338860	shares
CY2024Q1	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q1	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent		usd
CY2023Q1	nmtc	Stock Issued During Period Value Restricted Stock Unit Gross StockIssuedDuringPeriodValueRestrictedStockUnitGross		usd
CY2024Q1	nmtc	Stock Issued During Period Value Restricted Stock Unit Gross StockIssuedDuringPeriodValueRestrictedStockUnitGross		usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments		usd
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments		usd
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments		usd
	nmtc	Unpaid Deferred Issuance Costsoffset In Prepaids And Other Assets UnpaidDeferredIssuanceCostsoffsetInPrepaidsAndOtherAssets		usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability		usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability		usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent		usd
CY2024Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves		usd
CY2023Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent		usd
CY2023Q3	us-gaap	Deferred Revenue DeferredRevenue		usd
	us-gaap	Recognition Of Deferred Revenue RecognitionOfDeferredRevenue		usd
CY2024Q1	us-gaap	Deferred Revenue DeferredRevenue		usd
CY2023Q1	us-gaap	Deferred Revenue DeferredRevenue		usd
CY2024Q1	us-gaap	Deferred Revenue DeferredRevenue		usd
CY2024Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised		usd
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised		usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised		usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised		usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2024Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--09-30
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Entity Central Index Key EntityCentralIndexKey	0001500198

Files In Submission

Name	View Source	Status
0001213900-24-042948-index-headers.html	Edgar Link	pending
0001213900-24-042948-index.html	Edgar Link	pending
0001213900-24-042948.txt	Edgar Link	pending
0001213900-24-042948-xbrl.zip	Edgar Link	pending
ea0205459-10q_neuroone.htm	Edgar Link	pending
ea020545901ex31-1_neuroone.htm	Edgar Link	pending
ea020545901ex31-2_neuroone.htm	Edgar Link	pending
ea020545901ex32-1_neuroone.htm	Edgar Link	pending
ea020545901ex32-2_neuroone.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
nmtc-20240331.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
nmtc-20240331_cal.xml	Edgar Link	unprocessable
nmtc-20240331_def.xml	Edgar Link	unprocessable
nmtc-20240331_lab.xml	Edgar Link	unprocessable
nmtc-20240331_pre.xml	Edgar Link	unprocessable
ea0205459-10q_neuroone_htm.xml	Edgar Link	completed
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NMTC
NEUROONE MEDICAL TECHNOLOGIES Corp Stock $nmtc

2024 Q2 Form 10-Q Financial Statement

#000121390024042948 Filed on May 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NMTC NEUROONE MEDICAL TECHNOLOGIES Corp Stock $nmtc

2024 Q2 Form 10-Q Financial Statement

#000121390024042948 Filed on May 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NMTC
NEUROONE MEDICAL TECHNOLOGIES Corp Stock $nmtc